Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329907 | 0.89 | MCL1 (0.80) | MCL1KDM4EALDH1A1GPR35TTR | |
| SCHEMBL3498475 | 0.88 | MCL1 (0.78) | MCL1KDM4EALDH1A1GPR35TTR | |
| SCHEMBL4615856 | 0.87 | MCL1 (1.00) | MCL1KDM4EALDH1A1GPR35TTR | |
| SCHEMBL4655120 | 0.83 | MCL1 (0.71) | MCL1KDM4EALDH1A1GPR35MEN1 | |
| SCHEMBL11095441 | 0.83 | MCL1 (0.70) | MCL1KDM4EALDH1A1TTRKMT2A | |
| SCHEMBL4738325 | 0.81 | MCL1 (0.69) | MCL1KDM4EALDH1A1GPR35TTR | |
| SCHEMBL20893367 | 0.80 | MCL1 (0.67) | MCL1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4763051 | 0.80 | MCL1 (0.67) | MCL1KDM4EALDH1A1GPR35HPGD | |
| SCHEMBL16684635 | 0.80 | MCL1 (0.67) | MCL1KDM4EALDH1A1GPR35KCNH2 | |
| SCHEMBL10652526 | 0.80 | MCL1 (0.67) | MCL1KDM4EALDH1A1GPR35MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4829449-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| JP-2003508353-A | — | — | 2003-03-04 | — | — | JP | claimed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | claimed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | claimed |
| CN-113416216-B | High-activity Pt complex and preparation method and application thereof | 江苏南创化学与生命健康研究院有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113416216-B | High-activity Pt complex and preparation method and application thereof | 江苏南创化学与生命健康研究院有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113416216-A | High-activity Pt complex and preparation method and application thereof | 江苏南创化学与生命健康研究院有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-113416216-A | High-activity Pt complex and preparation method and application thereof | 江苏南创化学与生命健康研究院有限公司 | 2021-09-21 | — | — | CN | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| CN-1420882-A | Substd. oxoazaheterocyclyl compounds | AVENTIS PHARM PROD INC (US) | 2003-05-28 | — | — | CN | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | MCL1 2759/4885KDM4E 2943/4885ALDH1A1 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.